Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Improving Cognitive Functioning in People with Schizophrenia"
Deadline for manuscript submissions: closed (15 November 2019).
Interests: psychosis; bipolar disorder; depressive disorder; functioning; staging; precision psychiatry; cognitive remediation; early intervention; procognitive drugs; gut microbiota
Interests: psychosis; bipolar disorder; depressive disorder; functioning; staging; precision psychiatry; cognitive remediation; psychoeducation; early intervention; procognitive drugs; drug development
Schizophrenia is a chronic disorder characterized by psychotic symptoms such as hallucinations, delusions and disorganization and negative symptoms such as apathy and social withdrawal. It is also characterized by cognitive dysfunctions, which are present from the onset or even before the onset of the disorder. Cognitive impairment predicts disability and poor general functioning in the daily life of people diagnosed with schizophrenia. Although cognition is not a formal part of the current diagnostic criteria for schizophrenia, it is considered as a core feature of this illness.
Impairments in a broad range of cognitive domains have been consistently reported in individuals with schizophrenia, and persist throughout the course of the illness. Thus, interventions that are designed to treat cognitive symptoms are of high priority. Although antipsychotic medications help to treat positive symptoms of schizophrenia, the existing literature demonstrates that they have minimal effects on cognition. Nevertheless, the current studies on procognitive drugs seem to show encouraging results, and different meta-analytic studies have shown the efficacy of cognitive remediation. Several factors could affect cognitive function, and the evidence suggests that one of the main factors could be the cognitive reserve. Higher cognitive reserve is associated with a later onset of psychosis; greater illness insight; and better clinical, cognitive, and functional outcomes in people with schizophrenia. Thus, increasing cognitive reserve could become a skill that will allow people with schizophrenia to cope better with the disease and minimize their decline in cognitive and psychosocial functioning. The present Special Issue aims to go in-depth about the cognitive and functional impairment that people with schizophrenia suffer from and to describe the lines of research that are currently ongoing about enhancers of the cognitive and functional status of people with schizophrenia.
Dr. Iria Grande
Dr. Eduard Vieta
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- negative symptoms
- procognitive drugs
- cognitive reserve